Loading company…
Durham biotech developing ARCUS genome editing for genetic diseases, including chronic hepatitis B and cancer.
Precision BioSciences develops the ARCUS genome editing platform, which uses naturally occurring enzymes for precise DNA changes, for treating genetic diseases and cancer, including PBGENE-HBV for chronic hepatitis B and PBGENE-PMM for mitochondrial myopathy. Founded in 2006 by Jeff Smith and Derek Jantz and based in North Carolina, US, the company is at the Series B stage. In March 2026 it raised USD 7.5 million in venture funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in